NDA 020805 · Sandoz
Cipro Hc
Ciprofloxacin Hydrochloride, Hydrocortisone · Otic · Corticosteroid
Last checked: Nov 20, 2026Latest source record: Mar 20, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Feb 10, 1998
Approved uses
1
Original approval plus efficacy supplements
Registered trials
364
90 Phase 3, 32 recruiting
FAERS reports
20,745
13,575 serious, 1,437 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 29, 2026.
INDICATIONS AND USAGE Ciprofloxacin hydrochloride and hydrocortisone otic suspension is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa , Staphylococcus aureus , and Proteus mirabilis .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CIPRO HC · CIPROFLOXACIN HYDROCHLORIDE EQ 0.2% BASE; HYDROCORTISONE 1% · SUSPENSION/DROPS, OTIC · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ciprofloxacin" as an intervention, any sponsor and status, largest first.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit PatientsPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT02389036 · 20,010 participants · Start May 1, 2017 · Primary completion Apr 26, 2023
Drug: SDD Oral Paste; SDD Gastric Suspension and 1 more · For: Critical Illness; Sepsis; Septic Shock and 1 more
Sites: Sydney, Australia; Toronto, Canada; London, United Kingdom
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/SulfamethoxazolePivotal-lookingStatus unknown
Umeå UniversityAcademic, hospital or other
NCT02734732 · 2,800 participants (planned) · Start Apr 2015 · Primary completion Apr 2020
Drug: Trimethoprim/Sulfamethoxazole; Ciprofloxacin · For: Prostate Infection
Sites: Östersund, Sweden; Sundsvall, Sweden; Ängelholm, Sweden · 5 sites in all
- Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00014222 · 2,104 participants · Start Dec 4, 2000 · Primary completion Feb 10, 2014
Drug: epoetin alfa; filgrastim and 5 more · For: Breast Cancer
Sites: Fort Smith, Arkansas; Little Rock, Arkansas; La Jolla, California · 78 sites in all
University of WashingtonAcademic, hospital or other
NCT05286931 · 1,800 participants (planned) · Start Mar 3, 2022 · Primary completion Dec 31, 2025
Drug: Ciprofloxacin 500 mg · For: Neisseria Gonorrhoeae Infection
Sites: Seattle, Washington
- Antibiotic Prophylaxis Before Shock Wave LithotripsyPivotal-lookingCompleted
Clinical Urology and Epidemiology Working GroupGovernment (non-federal)
NCT03692715 · 1,732 participants · Start Sep 27, 2018 · Primary completion Dec 31, 2024
Drug: Ciprofloxacin; Placebo · For: Ureteral Stones; Ureteral Calculi; Nephrolithiasis
Sites: São Paulo, Brazil; London, Canada; Sherbrooke, Canada · 10 sites in all
- Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult WomenPivotal-lookingCompleted
Iterum Therapeutics, International LimitedIndustry
NCT03354598 · 1,671 participants · Start Aug 1, 2018 · Primary completion Jan 16, 2020
Drug: Sulopenem-Etzadroxil/Probenecid; Ciprofloxacin · For: Uncomplicated Urinary Tract Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Tolleson, Arizona · 60 sites in all
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) TrialPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02800785 · 1,552 participants · Start May 2016 · Primary completion Mar 5, 2020
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin · For: Appendicitis
Sites: Sylmar, California; Torrance, California; Aurora, Colorado · 25 sites in all
- Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.Pivotal-lookingCompleted
Radboud University Medical CenterAcademic, hospital or other
NCT03228108 · 1,538 participants · Start Apr 3, 2018 · Primary completion Sep 26, 2021
Drug: Ciprofloxacin; Trimethoprim/Sulfamethoxazole and 2 more · For: Complication; Infection; Prostate Cancer
Sites: 's-Hertogenbosch, Netherlands; Arnhem, Netherlands; Bergen op Zoom, Netherlands · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity2,484
- pain1,607
- neuropathy peripheral1,445
- nausea1,413
- diarrhoea1,408
- arthralgia1,388
- fatigue1,329
- urinary tract infection1,024
- dyspnoea991
- pain in extremity986
- headache985
- drug ineffective926
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 331 |
| 2005 | 401 |
| 2006 | 457 |
| 2007 | 319 |
| 2008 | 792 |
| 2009 | 659 |
| 2010 | 710 |
| 2011 | 685 |
| 2012 | 622 |
| 2013 | 1,034 |
| 2014 | 1,211 |
| 2015 | 1,694 |
| 2016 | 2,846 |
| 2017 | 1,533 |
| 2018 | 1,484 |
| 2019 | 1,842 |
| 2020 | 1,248 |
| 2021 | 870 |
| 2022 | 532 |
| 2023 | 476 |
| 2024 | 380 |
| 2025 | 404 |
| 2026 | 215 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Oct 30, 2026
Cipro, Otic Suspension/Drops, 0.2% base, 1% (NDC 66758-087-70). Discontinuation of the manufacturing of NDC 66758-087-70. Authorized generic is available under new NDC 0781-6218-70
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cipro HC (Ciprofloxacin/Hydrocortisone)
2024 spending
$3.7M
Beneficiaries
9,059
10,023 claims
Per beneficiary
$410
$36.56 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,234,454 |
| 2023 | $3,131,907 |
| 2024 | $3,712,181 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague.
Randremanana RV, Raberahona M, Bourner J, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis.
Hadidi MF, Alhamami N, Alhakami M, et al. · World J Urol 2024 · Systematic Review, Network Meta-Analysis
- Antimicrobial resistance in Vibrio cholerae O1/O139 clinical isolates: a systematic review and meta-analysis.
Liu C, Wang Y, Azizian K, et al. · Expert Rev Anti Infect Ther 2022 · Meta-Analysis, Systematic Review
- Antimicrobial resistance among clinical Vibrio cholerae non-O1/non-O139 isolates: systematic review and meta-analysis.
Wu Q, Vaziri AZ, Omidi N, et al. · Pathog Glob Health 2023 · Meta-Analysis, Systematic Review
- Cost-minimization analysis of oral versus intravenous antibiotic treatment for Klebsiella pneumoniae liver abscess.
Yoong J, Yuen KH, Molton JS, et al. · Sci Rep 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparing fosfomycin and ciprofloxacin for uncomplicated UTI treatment in adults: better bacterial eradication but non-significant clinical remission-a systematic review and meta-analysis.
Hashmi MU, Sufi Y, Zahoor T, et al. · Int Urol Nephrol 2025 · Systematic Review, Meta-Analysis
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.